+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
ZENLABS ZENLABS

Zenlabs Ethica Share Price

₹28.00 -0.56 (-1.96%)
29.98% Fall from 52W High

13 Nov, 2026 4:01 PM (IST)

Zenlabs Ethica live price: ₹28.00. It opened at ₹28 vs previous close ₹29; intraday high/low: ₹28/₹27. The 50 & 200 DMA stand at ₹27.60/₹28.00.

Zenlabs Ethica Performance

  • Today's Low
  • ₹27
  • Today's High
  • ₹28
  • 52 Week Low
  • ₹17
  • 52 Week High
  • ₹40
  • Open Price₹28
  • Previous Close₹29
  • Volume2,699
  • 50 DMA₹27.60
  • 100 DMA₹28.00
  • 200 DMA₹28.00

Zenlabs Ethica Chart

Investment Returns

  • Over 1 Month + 6.5%
  • Over 3 Month + 6.71%
  • Over 6 Month -2.78%
  • Over 1 Year -6.29%

Smart Investing Starts Here Start SIP with Zenlabs Ethica for Steady Growth!

Invest Now

Zenlabs Ethica Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -6.8
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 18
  • P/B Ratio
  • 2.3
  • Average True Range
  • 2.6
  • EPS
  • -4.1
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.1
  • RSI
  • 52.99
  • MFI
  • 80.89

Latest Stock News Updates

Zenlabs Ethica Ltd - 530697 - APPROVAL OF UNAUDITED FINANCIAL RESULTS OF THE COMPANY FOR THE QUARTER ENDED 30TH SEPTEMBER 2026

APPROVAL OF UNAUDITED FINANCIAL RESULTS OF THE COMPANY FOR THE QUARTER ENDED 30TH SEPTEMBER,2026

Zenlabs Ethica Ltd - 530697 - Board Meeting Outcome for Outcome Of The Board Meeting Held On 12Th November, 2026 For The Approval Of The Unaudited Financial Results For The Quarter Ended 30Th September 2026

Outcome of the board meeting held on 12th November, 2026 for the approval of the unaudited financial results for the quarter ended 30th September 2026

Zenlabs Ethica Ltd - 530697 - Board Meeting Intimation for Approval Of The Unaudited Financial Results For The Quarter Ended 30Th September, 2026

Zenlabs Ethica Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2026 ,inter alia, to consider and approve 1. Un-audited Financial Results of the Company for the Quarter ended September 30th 2026. 2. Any other matter with the permission of the Chair.

Zenlabs Ethica Financials

Zenlabs Ethica Technicals

EMA & SMA

Current Price
₹28.00
-0.56 (-1.96%)
pointer
  • Bearish Moving Average 5
  • Bullish Moving Average 11
  • 20 Day
  • ₹27.10
  • 50 Day
  • ₹27.60
  • 100 Day
  • ₹28.00
  • 200 Day
  • ₹28.00

Resistance and Support

27.63 Pivot Speed
  • R3 30.60
  • R2 29.50
  • R1 28.70
  • S1 26.90
  • S2 25.70
  • S3 25.00

Zenlabs Ethica Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-11-12 Quarterly Results
2026-08-12 Quarterly Results
2026-05-29 Audited Results
2026-02-07 Quarterly Results
2025-11-08 Quarterly Results
Date Purpose Remarks
2022-08-01 INTERIM Rs.0.25 per share(2.5%)Interim Dividend
View Zenlabs Ethica Dividend History Arrow

Zenlabs Ethica Shareholding Pattern

52.96%
47.04%
0%

About Zenlabs Ethica

Zenlabs Ethica is one of the leading marketing companies engaged in the trading and distribution of a wide range of branded pharmaceutical products across key therapeutic segments, including Gastrointestinal (GIT) disorders, Anti-Diabetics, Anti-Hypertensives, Anti-Infectives, Soa View More
  • NSE Symbol
  • ZENLABS
  • BSE Symbol
  • 530697
  • Executive Director,Managing Director,Chief Executive Officer
  • Mr. Sanjeev Kumar
  • ISIN
  • INE546F01013

Similar Stocks to Zenlabs Ethica

Zenlabs Ethica FAQs

Zenlabs Ethica share price is ₹28 As on 14 November, 2026 | 12:02

The Market Cap of Zenlabs Ethica is ₹18.2 Cr As on 14 November, 2026 | 12:02

The P/E ratio of Zenlabs Ethica is -6.8 As on 14 November, 2026 | 12:02

The PB ratio of Zenlabs Ethica is 2.3 As on 14 November, 2026 | 12:02

The 52 week High & Low of Zenlabs Ethica is ₹40/₹16.5 respectively As on 14 November, 2026 | 12:02

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23